Performance of Pulmonary Embolism Risk Scores Out Come in CTPA Confirmed Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-30

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients.
2. Compare PERFORM score with the currently validated PESI in risk stratification of patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk Assessment Strategies in Pulmonary Embolism

NCT04327960

Pulmonary Embolism

UNKNOWN

CTEPH Predictors Following Acute Pulmonary Embolism

NCT05784896

CTEPH Predictors

UNKNOWN

Clinical Pulmonary Embolism

NCT05469724

Acute Pulmonary Embolism

UNKNOWN

Surgery in Pulmonary Embolisms

NCT06070129

Pulmonary Embolism

NOT_YET_RECRUITING

A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.

NCT05098769

Pulmonary Embolism and Thrombosis Deterioration, Clinical

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pulmonary embolism (PE) is a common and potentially lethal condition in the emergency department requiring early and accurate management.

The short-term mortality rate of PE varies widely and ranges from less than 2% in many patients with non massive PE to more than 95% in patients who experience cardiorespiratory arrest.

Although several prognostic models of acute PE are currently used, all of them have practical limitations.

Of all clinical scores integrating PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) and its simplified version,(sPESI) have been most extensively validated to date.

However, current prognostic scores for pulmonary embolism (PE) are partly based on patients without PE confirmation via computed tomographic pulmonary angiography (CTPA), involving subjective parameters and complicated scoring methods \[8\].

Therefore, an objective, accurate, and simple prognostic model in CTPA-confirmed patients to predict the risk of 30-day mortality. help clinicians assess patients' risks and improve therapeutic decision-making that is called PERFORM score (pulmonary embolism risk score for mortality)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients above 18 years old with PE confirmed by CTPA are considered for inclusion in the study.

Exclusion Criteria

* • Patients who have contraindications for CTPA eg. Renal impairment

* Patients diagnosed and treated as PE without doing CTPA.
* Patients who refuse to participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No